DongKook Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
DongKook Pharmaceutical's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 10.5% per year. DongKook Pharmaceutical's return on equity is 8.6%, and it has net margins of 6.8%.
Key information
-2.4%
Earnings growth rate
-2.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 10.5% |
| Return on equity | 8.6% |
| Net Margin | 6.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well
May 29
We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt
May 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 06How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?
Mar 15The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?
Feb 28DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 14
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly
Feb 01DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 19The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio
Jan 06DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting
Dec 21What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?
Dec 08The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It
Nov 23Revenue & Expenses Breakdown
How DongKook Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 747,013 | 50,824 | 316,520 | 26,786 |
| 31 Dec 23 | 730,994 | 47,175 | 311,206 | 25,456 |
| 30 Sep 23 | 709,543 | 47,474 | 305,668 | 22,227 |
| 30 Jun 23 | 692,794 | 47,157 | 300,533 | 22,313 |
| 31 Mar 23 | 676,772 | 53,230 | 288,120 | 21,749 |
| 31 Dec 22 | 661,647 | 52,896 | 278,307 | 21,818 |
| 30 Sep 22 | 645,744 | 58,943 | 272,133 | 25,748 |
| 30 Jun 22 | 631,065 | 55,611 | 262,679 | 27,156 |
| 31 Mar 22 | 615,974 | 50,919 | 260,729 | 26,376 |
| 31 Dec 21 | 594,193 | 50,345 | 256,857 | 24,691 |
| 30 Sep 21 | 585,740 | 43,945 | 250,920 | 22,519 |
| 30 Jun 21 | 588,360 | 52,484 | 246,583 | 19,590 |
| 31 Mar 21 | 572,391 | 54,515 | 238,374 | 18,877 |
| 31 Dec 20 | 559,103 | 55,925 | 231,529 | 18,859 |
| 30 Sep 20 | 544,685 | 63,502 | 223,297 | 19,468 |
| 30 Jun 20 | 520,469 | 61,569 | 214,316 | 19,883 |
| 31 Mar 20 | 502,390 | 60,360 | 205,889 | 20,445 |
| 31 Dec 19 | 482,280 | 56,312 | 198,005 | 19,890 |
| 30 Sep 19 | 456,230 | 53,797 | 189,052 | 19,407 |
| 30 Jun 19 | 436,293 | 50,618 | 181,462 | 17,273 |
| 31 Mar 19 | 418,583 | 49,157 | 174,168 | 16,044 |
| 31 Dec 18 | 400,807 | 46,949 | 164,935 | 15,960 |
| 30 Sep 18 | 391,801 | 45,695 | 156,622 | 15,186 |
| 30 Jun 18 | 378,388 | 42,872 | 151,849 | 15,530 |
| 31 Mar 18 | 366,905 | 41,695 | 147,897 | 14,286 |
| 31 Dec 17 | 354,768 | 39,602 | 145,195 | 12,788 |
| 30 Sep 17 | 342,293 | 38,070 | 142,846 | 11,729 |
| 30 Jun 17 | 330,629 | 39,996 | 136,540 | 10,500 |
| 31 Mar 17 | 320,349 | 40,421 | 129,500 | 9,620 |
| 31 Dec 16 | 309,690 | 40,660 | 124,553 | 10,415 |
| 30 Sep 16 | 302,007 | 38,101 | 120,876 | 10,312 |
| 30 Jun 16 | 292,760 | 35,192 | 116,632 | 10,470 |
| 31 Mar 16 | 275,174 | 30,488 | 110,373 | 10,801 |
| 31 Dec 15 | 259,930 | 27,426 | 103,730 | 10,099 |
| 30 Sep 15 | 244,766 | 23,139 | 99,400 | 10,178 |
| 30 Jun 15 | 234,686 | 21,380 | 95,406 | 10,161 |
| 31 Mar 15 | 228,197 | 20,811 | 92,183 | 10,089 |
| 31 Dec 14 | 226,014 | 21,098 | 90,665 | 9,621 |
| 30 Sep 14 | 224,391 | 18,107 | 90,381 | 9,407 |
| 30 Jun 14 | 220,612 | 18,859 | 87,768 | 9,702 |
| 31 Mar 14 | 218,094 | 17,552 | 87,638 | 9,511 |
| 31 Dec 13 | 213,086 | 16,764 | 86,147 | 9,841 |
| 30 Sep 13 | 206,332 | 22,030 | 81,743 | 9,399 |
Quality Earnings: A086450 has high quality earnings.
Growing Profit Margin: A086450's current net profit margins (6.8%) are lower than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086450's earnings have declined by 2.4% per year over the past 5 years.
Accelerating Growth: A086450's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A086450 had negative earnings growth (-4.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.9%).
Return on Equity
High ROE: A086450's Return on Equity (8.6%) is considered low.